Start Date
February 28, 2019
Primary Completion Date
February 29, 2020
Study Completion Date
December 31, 2022
Belatacept
The transition to belatacept monotherapy and possibly to q 8 weeks administration can be safely done by applying personalized (i.e. precision) medicine. This includes phenotypic analysis of lymphocyte subsets, a quiescent molecular profiling of blood and urine prior to drug withdrawal and immune monitoring with KSORT after stepwise withdrawal of steroids and antiproliferatives. Furthermore, trough PK of belatacept will be measured for conversion to q 8 week therapy for discovering research purposes.
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
University of California, San Francisco
OTHER